Neuro-oncology (R Soffietti, Section Editor)

Diffuse Intrinsic Pontine Glioma: From Diagnosis to Next-Generation Clinical Trials

Nicholas A. Vitanza, MD[1,2,3]
Michelle Monje, MD, PhD[4,*]

Address
[1]Division of Hematology/Oncology, Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA, USA
[2]Center for Clinical and Translational Research, Seattle Children's Research Institute, Seattle, WA, USA
[3]Fred Hutchinson Cancer Research Center, Seattle, WA, USA
[*,4]Departments of Neurology and Neurological Sciences, Pediatrics, Stanford University Medical School, 265 Campus Drive, G3077, Stanford, CA, 94305, USA
Email: mmonje@stanford.edu

This article is part of the Topical Collection on *Neuro-oncology*

Abstract

Purpose of review This review of diffuse intrinsic pontine glioma (DIPG) provides clinical background, a systematic approach to diagnosis and initial care, and synthesizes historical, modern, and future directions for treatment. We present evidence supporting neurosurgical biopsy, early palliative care involvement, limitation of glucocorticoid use, and the leveraging of preclinical DIPG models as a pipeline to next-generation clinical trials.
Recent findings New molecular understanding of pediatric high-grade gliomas has led to the reclassification of DIPG as one member of a family of diffuse gliomas occurring in the midline of the central nervous system that exhibit pathognomonic mutations in genes encoding histone 3 (H3 K27M). DIPG remains a clinically relevant term, though diagnostically the 80% of DIPG cases that exhibit the H3 K27M mutation have been reclassified as diffuse midline glioma, H3 K27M-mutant. Re-irradiation has been shown to be well-tolerated and of potential benefit. Epigenetic targeting of transcriptional dependencies in preclinical models is fueling molecularly targeted clinical trials. Chimeric antigen receptor T cell immunotherapy has also demonstrated efficacy in preclinical models and provides a promising new clinical strategy.
Summary DIPG is a universally fatal, epigenetically driven tumor of the pons that is considered part of a broader class of diffuse midline gliomas sharing H3 K27M mutations.

Radiation remains the standard of care, single-agent temozolomide is not recommended, and glucocorticoids should be used only sparingly. A rapid evolution of understanding in the chromatin, signaling, and immunological biology of DIPG may soon result in clinical breakthroughs.

Introduction

While diffuse intrinsic pontine glioma (DIPG) has remained a fatal disease since Wilfred Harris' initial description of a pontine glioma in 1926, we now stand upon the precipice of clinical breakthroughs [1]. Scientific discoveries of the past decade have revolutionized our molecular understanding of DIPG, leading to a new diagnostic classification, "diffuse midline glioma, H3 K27M-mutant," based on pathognomonic histone 3 (H3) K27M mutations present in ∼ 80% of DIPG cases [2, 3••, 4••, 5••]. However, as DIPG and other diffusely infiltrating gliomas are not surgically resectable and many children are diagnosed based on the radiographic criteria alone, the molecular characteristics of each tumor are often not evaluated [6–8]. A lack of tissue for diagnosis and research has hampered progress; in comparison, other routinely resected pediatric central nervous system (CNS) tumors have been molecularly subgrouped with next-generation sequencing. Such granular subtype classifications in other pediatric CNS malignancies are beginning to enable tailored therapeutic approaches [9–11]. However, the combined power of new experimental models of DIPG and the demonstrated safety of neurosurgical biopsy has provided an avenue for translating preclinical testing to next-generation molecularly and immunologically targeted therapies that may soon make an impact on the lives of children with DIPG [12, 13•, 14, 15••, 16•, 17–20, 21•, 22–27].

Epidemiology

DIPG accounts for approximately 10% of all CNS tumors and 80% of all brainstem gliomas occurring in children, affecting ∼ 300 children per year in the United States (US) [28]. The median age at diagnosis is 6 to 7 years with a relatively equal sex distribution [29•, 30, 31]. With a median overall survival of only 9–11 months, DIPG represents the leading cause of brain tumor–related death in children [29•]. The median progression-free survival is 7 months and survival beyond progression is 2–4 months [29•]. Considering the median-affected age, the incidence, and the fatal prognosis, each year DIPG is responsible for approximately 24,000 years of potential life lost in the US. Rarely, DIPG also occurs in adults.

Diagnostic evaluation

Children affected by DIPG typically present following a median of 1 month of symptoms, although many present with as few as several days of symptoms; and occasionally, prodromes have been reported to be as long as 16 months [30]. Children frequently present with a triad of symptoms including ataxia, pyramidal tract dysfunction, and an abducens nerve (cranial nerve VI) palsy. The abducens palsy is present in the vast majority of children at diagnosis and is usually the first sign of DIPG [32]. In general, any potentially related symptoms

lasting longer than 6 months should prompt a broader differential of possible diagnoses including pilocytic astrocytoma, embryonal tumor, demyelinating disease, or vascular disease. In contrast to DIPG, pilocytic astrocytomas (WHO grade I) are most often exophytic and well-circumscribed, display a cyst/mural nodule formation, and are enhanced with contrast on magnetic resonance imaging (MRI). While DIPG most often originates in the ventral pons and presents acutely, exophytic low-grade gliomas of this region are more commonly tectal, pontomedullary, or cervicomedullary and present with indolent headaches or feeding intolerance [33]. Embryonal tumors commonly have a more heterogenous enhancement pattern on imaging and, at least in other CNS locations, produce extensive peritumoral edema. Large pediatric neurooncology practices regularly receive outside referrals for children with DIPG treated as another entity or observed for prolonged periods, as well as cases of suspected DIPG ultimately determined to be another diagnosis. Demyelinating processes are relatively rare in children and can often be distinguished from malignancy with MRI diffuse tensor imaging (DTI) fiber tracking [34].

The best diagnostic study to evaluate a child with suspected DIPG is an MRI of the brain with and without contrast, which will demonstrate an expanded pons and encasement of the basilar artery. The T2 FLAIR MRI sequence typically demonstrates signal in greater than 50% of the ventral pons (basis pontis; Fig. 1). Classically, DIPG does not exhibit contrast enhancement on T1 post-contrast images, though not infrequently there will be some areas of enhancement especially around foci of necrosis. Advanced MRI sequences may play a role in managing DIPG; one report indicates that apparent diffuse coefficient (ADC) images may distinguish distinct prognostic groups, and patients with high ADC values (> 1300) exhibited improved survival [35]. While the epicenter and origin of DIPG is within the pons, regional dissemination into the cerebellum, and even distant spread within the central nervous system, can be present at diagnosis. Dissemination throughout the central nervous system is common over the disease course; in a post-mortem review, disease was identified in the medulla (63%), midbrain (63%), lateral ventricles (63%), cerebellum (56%), thalamus (56%), frontal lobe (25%), and hippocampus (25%), as well as infratentorial leptomeningeal disease in 31% and supratentorial


Fig. 1. MRI images of a radiographically classic DIPG, including **a** axial T2 FLAIR and **b** sagittal T1 post-contrast images. Diffuse enlargement of the ventral pons and encasement of the basilar artery are classic signs.

leptomeningeal disease in 25% of patients [36]. Spinal cord disease at diagnosis is also possible, so we recommend MRI of the total spinal cord with and without contrast be performed in the event of any potentially related symptoms. Ongoing consideration of spinal imaging is warranted as DIPG can spread aggressively, even early in its clinical course. Historically, lumbar puncture has not been performed routinely in children with DIPG but considering the incidence of metastatic disease, it may be reasonable and is likely clinically safe to perform in children without evidence of hydrocephalus. Furthermore, while DIPG is not currently diagnosed via lumbar puncture, the advent of testing for circulating tumor DNA (ctDNA, detecting the H3 K27M mutation) soon may allow institutions without neurosurgical expertise in DIPG biopsy to evaluate molecular characteristics of this disease via CSF [37•, 38, 39]. Finding the H3 K27M mutation enables better prognostication for families and allows for consideration of early phase trials that may only be available for particular molecular subgroups.

Prior to the 2016 change in WHO nomenclature, DIPG histological grading ranged from WHO grades II to IV, although histological grade did not correlate with prognosis [2, 40]. However, the 2016 WHO CNS tumor reclassification defined a new entity that encompasses 80% of DIPG tumors: diffuse midline glioma, H3 K27M-mutant (DMG), which is by definition grade IV [2]. Many institutional and commercial sequencing platforms are able to identify the pathognomonic K27M mutations in the histone 3.3 (H3.3) gene *H3F3A*, histone 3.2 (H3.2) gene *HIST2H3C*, and histone 3.1 (H3.1) genes *HIST1H3B/C*, though the most cost-effective test is immunohistochemistry for the H3 K27M mutation (which does not distinguish between H3.3, H3.2, or H3.1 mutant variants) [41, 42]. Because the H3 K27M mutation results in dysfunction of the polycomb repressive complex II (PRC2) and subsequently in H3 K27 hypomethylation, immunostaining for H3 K27-me3 is complementary for H3 K27M-mutant gliomas of the pons and diffuse gliomas found in other midline structures such as the thalamus and spinal cord [43, 44]. The H3.1 variant occurs at a younger median age compared to the H3.3 variant, is more prevalent in females, and is only found in pontine DMG [45••]. The ~ 20% of DIPG tumors that do not express an H3 K27M mutation are not encompassed by the H3 K27M-mutant DMG definition and should not be overlooked as an important subgroup of DIPG tumors whose biology requires dedicated study.

Current treatments

In order to stabilize neurologic symptoms, dexamethasone is the most common initially prescribed treatment for children with newly diagnosed (or suspected) DIPG. A majority of children do not have hydrocephalus or require emergent neurosurgical intervention. A minority of children, either due to prolonged periods of symptom observation, large evolving necrotic centers, or biologically rapid disease, require emergent radiation and/or treatment of hydrocephalus (e.g., with a third ventriculostomy) [46]. Radiation oncologists should be consulted immediately even if a period of diagnostic evaluation and emotional preparation for families is planned prior to the initiation of radiotherapy. Stereotactic needle biopsy should be considered if the imaging appearance is not classical or if a tissue diagnosis will enable possible enrollment on a

molecularly stratified clinical trial. Molecular findings are required for some current clinical trials, and a minority of children may be found to have clinically actionable mutations even outside of clinical trials. The safety of pontine biopsy at experienced centers is highlighted in several reports, including a prospective evaluation of 50 children biopsied at 23 institutions that reported no procedure-related deaths and infrequent toxicity, with two grade 3 adverse events (apnea, hypertension) during the procedure and one subject with a neurological toxicity from which they did not recover (hemiparesis) [21•]. Experienced neurosurgeons can provide the most appropriate counseling, but, in brief, while neurological adverse events are rare, they can be severe [19, 21•, 24, 25, 27]. Biopsy should not inherently delay radiation as radiation planning can be done while neurosurgical biopsy is being considered.

Dexamethasone best serves as a bridge through possible neurosurgical biopsy and the initiation of radiation, but should be weaned off completely as quickly as tolerated due to adverse effects of corticosteroids including impaired sleep, impaired wound healing, increased appetite/weight gain, psychological and behavioral disturbances, diabetes mellitus, immunosuppression, and Cushing syndrome [47–50]. Dexamethasone may have an even more detrimental effect relating to the treatment of DIPG, as corticosteroids close the blood–brain barrier and thereby potentially limit tumor tissue penetration of potential systemic therapies [51, 52]. Furthermore, dexamethasone causes a specific gene-expression pattern in high-grade gliomas that portends a worse overall survival [53•, 54]. Ultimately, while dexamethasone may have a role in short bursts, children on prolonged steroids are at high risk for decreased quality of life. Tachyphylaxis to corticosteroids represents another reason to minimize corticosteroid use. The planned strategy for corticosteroid use and the expected side effects represents a conversation best initiated early with families and patients.

A critical early consideration should be the consultation of pediatric advanced care or pediatric palliative care specialists. Offering palliative care services to all patients with DIPG or DMG early in the course provides personalized support for the immediate and ongoing physical, psychological, social, and other effects this presently lethal prognosis will have on a family. Combined neuro-oncologic and palliative care support maximizes how patients and families function during their treatment and even can help to identify disease-related changes before otherwise clinically or radiographically suspected progression [55].

Focal radiotherapy remains the standard of care for children with DIPG and increases overall survival by ∼3 months; without radiotherapy, overall survival is only ∼5 months [56]. Radiation is most commonly delivered using photon radiotherapy conformally delivered to the tumor at 54 Gy in 1.8-Gy daily fractions over 6 weeks. A hypo-fractionated approach using 39 Gy in 13–16 fractions appears to have similar outcomes and results in less medical burden, especially for young children requiring sedation [57, 58]. A hyperfractionated approach to 78 Gy did not provide a survival benefit and potentially increased steroid dependence and a severely hypo-fractionated approach of 25 Gy in only 5 fractions may have shortened survival and increased radiation necrosis [59, 60]. After disease progression, re-irradiation may also be considered. Re-irradiation regimens of approximately 25 Gy over 10 fractions

repeatedly have been demonstrated to be safe and suggest a modest survival benefit, as well as a stabilization or improvement in symptoms [61–64].

More than 200 clinical trials of conventional cytotoxic and myeloablative chemotherapy have failed to improve survival in children with DIPG [65]. Radiosensitizing agents during radiotherapy have thus far failed to improve survival [66–68]. Likewise, intensive chemotherapeutic treatment regimens, including myeloablative dosing requiring stem cell transplantation, have not shown promise [69, 70]. Despite modest efficacy in adult high-grade gliomas, single-agent temozolomide does not improve DIPG outcomes in either conventional or metronomic dosing [71–74]. Most recently, gemcitabine, capecitabine, several tyrosine kinase inhibitors most often targeting VEGF or EGFR, and an EGFR monoclonal antibody have been evaluated in DIPG without major improvements in survival, although the EGFR inhibitor gefitinib's 1-year median OS of 56% is higher than many historical reports [75–83]. This overall lack of response to traditional chemotherapeutic agents is concordant with a broad lack of response to most cytotoxic chemotherapeutics of DIPG cell cultures in drug screens, and underscores the need for therapies targeting the unique biology of DIPG and an effective means by which to deliver those putative therapies to this cancer with a relatively intact blood–brain barrier [20].

Future treatments

The advent of genetically engineered and patient-derived experimental models now provides a critical avenue for deepening our biological understanding of DIPG and preclinical therapeutic testing [17, 18, 22, 23, 26]. Epigenetically targeted agents are of particular interest, both conceptually and empirically from preclinical drug screens [20]. Supported by preclinical studies, the clinical efficacy of the HDAC inhibitor panobinostat is now being evaluated in several clinical trials (e.g., NCT02717455) [20]. A subsequent preclinical study of epigenetic strategies identified several other agents that target oncogenic transcription, such as through CDK7 blockade or bromodomain inhibition [15••]. While not ready for clinical translation, jumonji demethylase inhibitors also appear to exhibit modest preclinical benefit, enforcing the concept of targeting aberrant transcription in DIPG [84].

Immunotherapeutic agents including vaccine therapies, oncolytic viruses, checkpoint blockade, and chimeric antigen receptor (CAR) T cells account for the upcoming next wave of DIPG clinical trials as more experience is garnered in other CNS tumors [13•, 85•, 86]. Critically, recent independent evaluations revealed the DIPG microenvironment to be neither highly immunosuppressive nor inflammatory, making it fundamentally different from adult glioblastoma [14, 16•]. In the absence of innate immunosuppression, CAR T cells are particularly promising on the heels of their revolutionary benefit in leukemia [87]. In preclinical in vivo studies, CAR T cells targeting GD2, a disialoganglioside highly expressed in H3 K27M-mutant DMG, eradicated H3 K27M-mutant DMG tumors in xenograft models; additional targets for CAR T cell therapy such as B7H3

have also recently come to light [88•, 89•]. A clinical trial of GD2-specific CAR T cell therapy for DIPG is presently in preparation. Currently, clinical trials of HER2-specific CAR T cells (BrainChild-01, NCT03500991) and EGFR806-specific CAR T cells (BrainChild-02, NCT03638167) are evaluating locoregional delivery of CAR T cells in children with refractory or recurrent CNS tumors. While these have excluded DIPG, their insight into CNS inflammatory responses will inform BrainChild-03, a clinical trial of B7-H3-specific CAR T cells presently in preparation for children with DIPG.

Finally, novel therapy delivery strategies are emerging including convection-enhanced delivery (CED), in which catheter tips are neurosurgically inserted into the pons and a pressure gradient is used to deliver regional therapy [90]. While DIPG is often a metastatic disease, the most critical pontine disease does likely have innate protection from systemic chemotherapy, such as through the blood–brain barrier or intrinsic high pressure, so CED is currently being evaluated in early phase clinical trials [91].

Conclusion

DIPG remains a universally fatal disease with a median survival of under 1 year. While the diagnosis is often made by MRI, neurosurgical biopsy is safe and is becoming more common in an effort for improved diagnosis, prognostication, and therapeutic targeting. The discovery of H3 K27M mutations has revolutionized our understanding of DIPG biology, creating the new diagnostic class H3 K27M-mutant diffuse midline gliomas, which includes thalamic and spinal tumors with similarly dismal prognoses. Radiation remains the mainstay of therapy, and re-irradiation at the time of tumor progression appears safe and can confer modest improvements in symptoms and in survival. Glucocorticoid use should be carefully minimized, and single-agent temozolomide has no role in DIPG therapy. The H3 K27M mutation results in transcriptional dependencies that may be leveraged with epigenetically targeted agents, some of which are currently being evaluated in clinical trials. Complimentary preclinical models of DIPG form the foundation of a preclinical to clinical pipeline as we further investigate the role of immunotherapies and, ultimately, combinatorial approaches targeting both cell-intrinsic vulnerabilities and microenvironmental dependencies in the search for a cure of this seemingly intractable childhood brain cancer.

Acknowledgements

Compliance with Ethical Standards

Conflict of Interest
Nicholas A. Vitanza declares no potential conflicts of interest. Michelle Monje has a pending patent entitled "CAR T cell therapy to treat H3K27M midline gliomas."

Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as:
- •   Of importance
- ••   Of major importance

1. Harris W. A case of pontine glioma, with special reference to the paths of gustatory sensation. Proc R Soc Med. 1926;**19**(Neurol Sect):1–5.
2. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20.
3.•• Khuong-Quang DA, Buczkowicz P, Rakopoulos P, et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol. 2012;124(3):439–47.
4.•• Wu G, Broniscer A, McEachron TA, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet. 2012;44(3):251–3.
5.•• Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodeling genes in pediatric glioblastoma. Nature. 2012;**482**(7384):226–31.

Wu et al., Khuong-Quang et al. and Schwartzentruber et al. discovered the highly recurrent H3 K27M mutation in DIPG and other pediatric midline gliomas. This discovery of an "oncohistone" has revolutionized our understanding of the pathophysiology of this disease and underscores the central role for epigenetic dysregulation in DIPG and other pediatric malignancies.

6. Albright AL, Packer RJ, Zimmerman R, et al. Magnetic resonance scans should replace biopsies for the diagnosis of diffuse brain stem gliomas: a report from the Children's Cancer Group. Neurosurgery. 1993;33(6):1026–9 discussion 1029–30.
7. Hankinson TC, Campagna EJ, Foreman NK, et al. Interpretation of magnetic resonance images in diffuse intrinsic pontine glioma: a survey of pediatric neurosurgeons. J Neurosurg Pediatr. 2011;8(1):97–102.
8. Barkovich AJ, Krischer J, Kun LE, et al. Brain stem gliomas: a classification system based on magnetic resonance imaging. Pediatr Neurosurg. 1990;16(2):73–83.
9. Pajtler, K.W., S.C. Mack, V. Ramaswamy, et al. The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathol. 2016.
10. Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012;123(4):465–72.
11. Reis GF, Tihan T. Therapeutic targets in pilocytic astrocytoma based on genetic analysis. Semin Pediatr Neurol. 2015;22(1):23–7.
12. Lapin DH, Tsoli M, Ziegler DS. Genomic insights into diffuse intrinsic pontine glioma. Front Oncol. 2017;7:57.
13.• Lieberman NAP, Vitanza NA, Crane CA. Immunotherapy for brain tumors: understanding early successes and limitations. Expert Rev Neurother. 2018;18(3):251–9.
14. Lieberman NAP, DeGolier K, Kovar HM, et al. Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy. Neuro Oncol. 2019;**21**(1):83–94.
15.•• Nagaraja S, Vitanza NA, Woo PJ, et al. Transcriptional dependencies in diffuse intrinsic pontine glioma. Cancer Cell. 2017, 31(5):635–652 e6.

This preclinical work discovered DIPG's vulnerabilities to BRD4 and CDK7 blockade, as well as their synergistic benefit when combined with HDAC inhibition.

16.• Lin GL, Nagaraja S, Filbin MG, et al. Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma. Acta Neuropathol Commun. 2018;6(1):5.

Lin et al. and Lieberman et al. independently discovered the microenvironment in DIPG is neither immunosuppresive nor inflammatory, making it distinct from that of adult GBM.

17. Becher OJ, Hambardzumyan D, Walker TR, et al. Pre-clinical evaluation of radiation and perifosine in a

genetically and histologically accurate model of brainstem glioma. Cancer Res. 2010;70(6):2548–57.

18. Biery, M., C. Myers, E. Girard, et al. A novel HDAC inhibitor in new patient-derived diffuse intrinsic pontine glioma (DIPG) models, in ISPNO2018 - International Symposium on Pediatric Neuro-Oncology. DIPG-35, Presentation. 2018: Denver, CO, USA. p. i56.

19. Cage TA, Samagh SP, Mueller S, et al. Feasibility, safety, and indications for surgical biopsy of intrinsic brainstem tumors in children. Childs Nerv Syst. 2013;29(8):1313–9.

20. Grasso CS, Tang Y, Truffaux N, et al. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat Med. 2015;21(6):555–9.

21.• Gupta, N., L.C. Goumnerova, P. Manley, et al. Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. Neuro Oncol. 2018;20(11):1547–1555.

An important prospective study evaluating the safety of biopsy for patients with DIPG.

22. Larson JD, Kasper LH, Paugh BS, et al. Histone H3.3 K27M accelerates spontaneous brainstem glioma and drives restricted changes in bivalent gene expression. Cancer Cell. 2019;35(1):140–155 e7.

23. Lin GL, Monje M. A protocol for rapid post-mortem cell culture of diffuse intrinsic pontine glioma (DIPG). J Vis Exp. 2017;(121).

24. Puget S, Beccaria K, Blauwblomme T, et al. Biopsy in a series of 130 pediatric diffuse intrinsic pontine gliomas. Childs Nerv Syst. 2015;31(10):1773–80.

25. Roujeau T, Machado G, Garnett MR, et al. Stereotactic biopsy of diffuse pontine lesions in children. J Neurosurg. 2007;107(1 Suppl):1–4.

26. Tsoli M, Shen H, Mayoh C, et al. International experience in the development of patient-derived xenograft models of diffuse intrinsic pontine glioma. J Neurooncol. 2018.

27. Wang ZJ, Rao L, Bhambhani K, et al. Diffuse intrinsic pontine glioma biopsy: a single institution experience. Pediatr Blood Cancer. 2015;62(1):163–5.

28. Freeman CR, Farmer JP. Pediatric brain stem gliomas: a review. Int J Radiat Oncol Biol Phys. 1998;40(2):265–71.

29.• Cooney T, Lane A, Bartels U, et al. Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study. Neuro Oncol. 2017;19(9):1279–80

An important update on international survival endpoints for children with DIPG.

30. Veldhuijzen van Zanten SE, Jansen MH, Sanchez Aliaga E, et al. A twenty-year review of diagnosing and treating children with diffuse intrinsic pontine glioma in The Netherlands. Expert Rev Anticancer Ther. 2014;15(2):157–64

31. Lassman LP, Arjona VE. Pontine gliomas of childhood. Lancet. 1967;**1**(7496):913–5.

32. Fisher PG, Breiter SN, Carson BS, et al. A clinicopathologic reappraisal of brain stem tumor classification.

33. Identification of pilocystic astrocytoma and fibrillary astrocytoma as distinct entities. Cancer. 2000;89(7):1569–76.

33. Fried I, Hawkins C, Scheinemann K, et al. Favorable outcome with conservative treatment for children with low grade brainstem tumors. Pediatr Blood Cancer. 2012;58(4):556–60.

34. Giussani C, Poliakov A, Ferri RT, et al. DTI fiber tracking to differentiate demyelinating diseases from diffuse brain stem glioma. Neuroimage. 2010;52(1):217–23.

35. Lober RM, Cho YJ, Tang Y, et al. Diffusion-weighted MRI derived apparent diffusion coefficient identifies prognostically distinct subgroups of pediatric diffuse intrinsic pontine glioma. J Neurooncol. 2014;117(1):175–82.

36. Caretti V, Bugiani M, Freret M, et al. Subventricular spread of diffuse intrinsic pontine glioma. Acta Neuropathol. 2014;128(4):605–7.

37.• Huang TY, Piunti A, Lulla RR, et al. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma. Acta Neuropathol Commun. 2017;**5**(1):28.

Considering DIPG biopsy's requirement of neurosurgical precision, limited availability, low but significant risk of complications, and the decision's emotional toll on families, this is an important study showing histone H3 mutations can be detected in CSF.

38. Saratsis AM, Yadavilli S, Magge S, et al. Insights into pediatric diffuse intrinsic pontine glioma through proteomic analysis of cerebrospinal fluid. Neuro Oncol. 2012;14(5):547–60.

39. Pan C, Diplas BH, Chen X, et al. Molecular profiling of tumors of the brainstem by sequencing of CSF-derived circulating tumor DNA. Acta Neuropathol. 2018;137(2):297–306.

40. Buczkowicz P, Bartels U, Bouffet E, et al. Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications. Acta Neuropathol. 2014;128(4):573–81.

41. Bozkurt SU, Dagcinar A, Tanrikulu B, et al. Significance of H3K27M mutation with specific histomorphological features and associated molecular alterations in pediatric high-grade glial tumors. Childs Nerv Syst. 2018;34(1):107–16.

42. Pritchard CC, Salipante SJ, Koehler K, et al. Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. J Mol Diagn. 2014;16(1):56–67.

43. Lewis PW, Muller MM, Koletsky MS, et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science. 2013;340(6134):857–61.

44. Shankar GM, Lelic N, Gill CM, et al. BRAF alteration status and the histone H3F3A gene K27M mutation segregate spinal cord astrocytoma histology. Acta Neuropathol. 2016;131(1):147–50.

45.•• Mackay A, Burford A, Carvalho D, et al. Integrated molecular meta-analysis of 1000 pediatric high-grade

and diffuse intrinsic pontine glioma. Cancer Cell. 2017;32(4):520–537.
A comprehensive analysis of DIPG's molecular aberrations and their clinical significance.

46. Guida L, Roux FE, Massimino M, et al. Safety and efficacy of endoscopic third ventriculostomy in diffuse intrinsic pontine glioma related hydrocephalus: a systematic review. World Neurosurg. 2019;124:29–35.

47. Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335(1):2–13.

48. Drozdowicz LB, Bostwick JM. Psychiatric adverse effects of pediatric corticosteroid use. Mayo Clin Proc. 2014;89(6):817–34.

49. Goforth P, Gudas CJ. Effects of steroids on wound healing: a review of the literature. J Foot Surg. 1980;19(1):22–8.

50. Pappachan JM, Hariman C, Edavalath M, et al. Cushing's syndrome: a practical approach to diagnosis and differential diagnoses. J Clin Pathol. 2017;70(4):350–9.

51. Fauquette W, Amourette C, Dehouck MP, et al. Radiation-induced blood-brain barrier damages: an in vitro study. Brain Res. 2012;1433:114–26.

52. Hue CD, Cho FS, Cao S, et al. Dexamethasone potentiates in vitro blood-brain barrier recovery after primary blast injury by glucocorticoid receptor-mediated upregulation of ZO-1 tight junction protein. J Cereb Blood Flow Metab. 2015;35(7):1191–8.

53.• Luedi MM, Singh SK, Mosley JC, et al. A dexamethasone-regulated gene signature is prognostic for poor survival in glioblastoma patients. J Neurosurg Anesthesiol. 2017;**29**(1):46–58.
This work highlights the importance of limiting steroid use in our patients.

54. Pitter KL, Tamagno I, Alikhanyan K, et al. Corticosteroids compromise survival in glioblastoma. Brain. 2016;139(Pt 5):1458–71.

55. Mandrell BN, Baker J, Levine D, et al. Children with minimal chance for cure: parent proxy of the child's health-related quality of life and the effect on parental physical and mental health during treatment. J Neurooncol. 2016;129(2):373–81.

56. Langmoen IA, Lundar T, Storm-Mathisen I, et al. Management of pediatric pontine gliomas. *Childs Nerv Syst.* 1991;**7**(1):13–5.

57. Janssens GO, Jansen MH, Lauwers SJ, et al. Hypofractionation vs conventional radiation therapy for newly diagnosed diffuse intrinsic pontine glioma: a matched-cohort analysis. Int J Radiat Oncol Biol Phys. 2013;85(2):315–20.

58. Zaghloul MS, Eldebawy E, Ahmed S, et al. Hypofractionated conformal radiotherapy for pediatric diffuse intrinsic pontine glioma (DIPG): a randomized controlled trial. Radiother Oncol. 2014;111(1):35–40.

59. Hankinson TC, Patibandla MR, Green A, et al. Hypofractionated radiotherapy for children with diffuse intrinsic pontine gliomas. Pediatr Blood Cancer. 2015.

60. Packer RJ, Boyett JM, Zimmerman RA, et al. Outcome of children with brain stem gliomas after treatment with 7800 cGy of hyperfractionated radiotherapy. A Childrens Cancer Group Phase I/II Trial. Cancer. 1994;74(6):1827–34.

61. Freese C, Takiar V, Fouladi M, et al. Radiation and subsequent reirradiation outcomes in the treatment of diffuse intrinsic pontine glioma and a systematic review of the reirradiation literature. Pract Radiat Oncol. 2017;**7**(2):86–92.

62. Janssens GO, Gandola L, Bolle S, et al. Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: a matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group. Eur J Cancer. 2017;73:38–47.

63. Lassaletta A, Strother D, Laperriere N, et al. Reirradiation in patients with diffuse intrinsic pontine gliomas: the Canadian experience. Pediatr Blood Cancer. 2018;65(6):e26988.

64. Morales La Madrid A, Santa-Maria V, Cruz Martinez O, et al. Second re-irradiation for DIPG progression, reconsidering "old strategies" with new approaches. Childs Nerv Syst. 2017;33(5):849–52.

65. Robison NJ, Kieran MW. Diffuse intrinsic pontine glioma: a reassessment. J Neurooncol. 2014;119(1):7–15.

66. Aquino-Parsons C, Hukin J, Green A. Concurrent carbogen and radiation therapy in children with high-risk brainstem gliomas. Pediatr Blood Cancer. 2008;50(2):397–9.

67. Bradley KA, Zhou T, McNall-Knapp RY, et al. Motexafin-gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a children's oncology group phase 2 study. Int J Radiat Oncol Biol Phys. 2013;85(1):e55–60.

68. Freeman CR, Kepner J, Kun LE, et al. A detrimental effect of a combined chemotherapy-radiotherapy approach in children with diffuse intrinsic brain stem gliomas? Int J Radiat Oncol Biol Phys. 2000;47(3):561–4.

69. Massimino M, Spreafico F, Biassoni V, et al. Diffuse pontine gliomas in children: changing strategies, changing results? A mono-institutional 20-year experience. J Neurooncol. 2008;87(3):355–61.

70. Wagner S, Warmuth-Metz M, Emser A, et al. Treatment options in childhood pontine gliomas. J Neurooncol. 2006;79(3):281–7.

71. Cohen KJ, Heideman RL, Zhou T, et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. Neuro Oncol. 2011;13(4):410–6.

72. Jalali R, Raut N, Arora B, et al. Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys. 2010;77(1):113–8.

73. Sharp JR, Bouffet E, Stempak D, et al. A multi-centre Canadian pilot study of metronomic temozolomide

combined with radiotherapy for newly diagnosed paediatric brainstem glioma. Eur J Cancer. 2010;46(18):3271–9.

74.   Bailey S, Howman A, Wheatley K, et al. Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy–results of a United Kingdom phase II trial (CNS 2007 04). Eur J Cancer. 2013;49(18):3856–62.

75.   Broniscer A, Baker JN, Tagen M, et al. Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. J Clin Oncol. 2010;28(31):4762–8.

76.   Broniscer A, Baker SD, Wetmore C, et al. Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma. Clin Cancer Res. 2013;19(11):3050–8.

77.   Geoerger B, Hargrave D, Thomas F, et al. Innovative therapies for children with cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro Oncol. 2011;13(1):109–18.

78.   Haas-Kogan DA, Banerjee A, Poussaint TY, et al. Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. Neuro Oncol. 2011;13(3):298–306.

79.   Pollack IF, Jakacki RI, Blaney SM, et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol. 2007;9(2):145–60.

80.   Bartels U, Wolff J, Gore L, et al. Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma. Neuro Oncol. 2014;16(11):1554–9.

81.   Veldhuijzen van Zanten SEM, El-Khouly FE, Jansen MHA, et al. A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma. J Neurooncol. 2017;135(2):307–15.

82.   Kilburn LB, Kocak M, Baxter P, et al. A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas. Pediatr Blood Cancer. 2018;65(2):e26832.

83.   Pollack IF, Stewart CF, Kocak M, et al. A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium. Neuro Oncol. 2011;13(3):290–7.

84.   Hashizume R, Andor N, Ihara Y, et al. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat Med. 2014;20(12):1394–6.

85.•   Vitanza NA, Johnson A, Beebe A, et al. Locoregional HER2CAR T cells for pediatric central nervous system tumors: preclinical efficacy to tolerability in first patient. IMMU-02, Oral Presentation, in Society of Neuro-Oncology Pediatric Basic and Translational Research Conference. 2019: San Francisco, CA.

This work highlights the initial patient experience in locoregionally delivering HER2 CAR T cells to children with recurrent/refractory CNS tumors, providing a framework for future locoregional DIPG CAR T cell trials.

86.   Ahmed N, Brawley V, Hegde M, et al. HER2-Specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol. 2017;3(8):1094–101.

87.   Gardner RA, Finney O, Annesley C, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129(25):3322–31.

88.•   Mount CW, Majzner RG, Sundaresh S, et al. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M(+) diffuse midline gliomas. Nat Med. 2018;24(5):572–9.

The first published DIPG-specific preclinical CAR T cell work, highlighting the vulnerability of targeting GD2.

89.•   Majzner RG, Theruvath JL, Nellan A, et al. CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin Cancer Res. 2019;25(8):2560–2574.

B7-H3 has been identified as a surface antigen present in many pediatric CNS tumors and this preclinical work served as the foundation for upcoming B7-H3 CAR T cell trials for pediatric CNS tumors including DIPG.

90.   Halle B, Mongelard K, Poulsen FR. Convection-enhanced drug delivery for glioblastoma: a systematic review focused on methodological differences in the use of the convection-enhanced delivery method. Asian J Neurosurg. 2019;14(1):5–14.

91.   Souweidane MM, Kramer K, Pandit-Taskar N, et al. Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial. Lancet Oncol. 2018;19(8):1040–50.

Publisher's Note